Nuria de la Iglesia
Overview
Explore the profile of Nuria de la Iglesia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munoz-Marmol A, Melendez B, Hernandez A, Sanz C, Domenech M, Arpi-Llucia O, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941744
We explored the rationale for treating glioblastoma (GBM) with regorafenib. In 103 newly diagnosed GBM patients, we assessed mutations, copy number variants (CNVs), fusions, and overexpression in 46 genes encoding...
2.
de la Iglesia N, Konopka G, Puram S, Chan J, Bachoo R, You M, et al.
Genes Dev
. 2025 Feb;
39(3-4):299.
PMID: 39900475
No abstract available.
3.
Gorria T, Crous C, Pineda E, Hernandez A, Domenech M, Sanz C, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398126
Materials And Methods: mutations were assessed in a retrospective cohort of 258 uniformly treated glioblastoma patients. RNA-sequencing and whole exome sequencing results were available in a subset of patients. Results:...
4.
Blanco-Heredia J, Souza C, Trincado J, Gonzalez-Cao M, Goncalves-Ribeiro S, Gil S, et al.
Nat Commun
. 2024 Feb;
15(1):1302.
PMID: 38383522
The interactions between tumor and immune cells along the course of breast cancer progression remain largely unknown. Here, we extensively characterize multiple sequential and parallel multiregion tumor and blood specimens...
5.
Barajas A, Amengual-Rigo P, Pons-Grifols A, Ortiz R, Carmona O, Urrea V, et al.
J Transl Med
. 2024 Jan;
22(1):14.
PMID: 38172991
Background: Neoantigens are patient- and tumor-specific peptides that arise from somatic mutations. They stand as promising targets for personalized therapeutic cancer vaccines. The identification process for neoantigens has evolved with...
6.
Martinez-Bosch N, Vilarino N, Alameda F, Mojal S, Arumi-Uria M, Carrato C, et al.
Cells
. 2023 Mar;
12(6).
PMID: 36980184
Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have...
7.
Aguilar-Gurrieri C, Barajas A, Rovirosa C, Ortiz R, Urrea V, de la Iglesia N, et al.
Cancer Immunol Immunother
. 2023 Feb;
72(7):2113-2125.
PMID: 36820900
Neoantigens are tumor-specific antigens that are mostly particular for each patient. Since the immune system is able to mount a specific immune response against these neoantigens, they are a promising...
8.
Hernandez A, Munoz-Marmol A, Esteve-Codina A, Alameda F, Carrato C, Pineda E, et al.
Sci Rep
. 2022 Aug;
12(1):14439.
PMID: 36002559
RNA-Sequencing (RNA-Seq) can identify gene fusions in tumors, but not all these fusions have functional consequences. Using multiple data bases, we have performed an in silico analysis of fusions detected...
9.
Stanzani E, Pedrosa L, Bourmeau G, Anezo O, Noguera-Castells A, Esteve-Codina A, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34205341
Therapeutic resistance after multimodal therapy is the most relevant cause of glioblastoma (GBM) recurrence. Extensive cellular heterogeneity, mainly driven by the presence of GBM stem-like cells (GSCs), strongly correlates with...
10.
Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpi O, Martinez-Garcia M, et al.
Clin Cancer Res
. 2020 Oct;
27(2):645-655.
PMID: 33106291
Purpose: Glioblastoma is the most aggressive brain tumor in adults and has few therapeutic options. The study of molecular subtype classifications may lead to improved prognostic classification and identification of...